Effects of TNFalpha, NOS3, MDR1 gene polymorphisms on clinical parameters, prognosis and survival of multiple myeloma cases

Asian Pacific Journal of Cancer Prevention

Volumn 17, Issue 3, 2016, Pages 1009-1014

  Basmaci, C ^a   Pehlivan, M ^a   Tomatir, A G ^b   Sever, T ^a   Okan, V ^a   Yilmaz, M ^a   Oguzkan Balci, S ^a   Pehlivan, S ^c  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

MDR1; Multiple myeloma; NOS3 (+894, VNTR); TNFalpha ( 308, 238 and 857)

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN; NOS3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALLELE; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NITRIC OXIDE SYNTHASE TYPE III; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84965002765     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2016.17.3.1009     Document Type: Article

References (32)

1. Akcali A, Pehlivan S, Pehlivan M, et al (2010). TNF-alpha promoter polymorphisms in multiple sclerosis: no association with -308 and -238 alleles, but the -857 alleles in associated with the disease in Turkish patients. Int J Immunogenet, 37, 91-5
2. Banu C, Moise A, Arion CV, et al (2011). Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients. J Med Life, 4, 264-8
3. Bivalacqua TJ, Champion HC, Hellstrom WJG (2002). Implications of nitric oxide synthases isoforms in the pathophysiology of Peyronie's disease. Int J Imp Res, 14, 345-2
4. Black RA, Rauch CT, Kozlosky CJ, et al (1997). A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 385, 729-33
5. Buda G, Maggini V, Galimberti S, et al (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol. 137, 454-6
6. Buda G, Ricci D, Huang CC, et al (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 89, 1133-40
7. Cox DR (1972). Regression models and life-tables. J R Stat Soc Ser B, 34, 187-220
8. Dogra S, Khullar G (2013). Tumor necrosis factor-α antagonists: Side effects and their management. Indian J Dermatol Venereol Leprol, 7, 35-46
9. Drain S, Catherwood MA, Orr N, et al (2009). ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma, 50, 566-570
10. Du J, Yuan ZG, Zhang CY, et al (2009). Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghau Xue Ye Xeu Za Zhi, 30, 649-53
11. Game X, Rischmann P, Arnal JF, et al (2013). Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role]. Prog Urol, 23, 926-35
12. Germann, UA (1996). P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer. 32, 927-44
13. Ghilardi G, Biondi ML, Cecchini F, et al (2003). Vasculer invasion in human breast cancer is coralated to T->786C polymophism of NOS3 gene. Nitric Oxide, 9, 118-22
14. Hefler LA, Grimm C, Lantzsch T, et al (2006). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat, 98, 151-55
15. Hefler LA, Ludwig E, Lampe D, et al (2002). Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. Gynecol Oncol, 86, 134-37
16. Heil M, Eitenmuller I, Schmitz-Rixen T, et al (2006). Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med, 10, 45-55
17. Ichimaru M, Ishimaru T, Mikami M, et al (1982). Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: Relationship to radiation dose absorbed by marrow. J Natl Cancer Inst, 69, 323-28
18. Iokupova EV, Grinchuk OV, Kalimullina DKH, et al (2003). Molecular genetic analysis of the IL-6 and Tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk), 37, 420-24
19. Jamroziak K, Balcerczak E, Cebula B, et al (2005). Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep, 57, 882-8
20. Juliano RL, Ling VA (1976). Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62
21. Kadar K, Kovacs M, Karadi I, et al (2008). Polymorphism of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 32, 1499-504
22. Kaplan EL, Meier P (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81
23. Knop S (2014). The multiple myeloma -current view and perspectives. Med Monatsshr Pharm, 37, 84-92
24. Kyle RA (1994). Multiple myeloma: How did it begin? Mayo Clin Proc, 69, 680-83
25. Medeiros R, Morais A, Vasconcelos A, et al (2002). Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev, 11, 343-50
26. Nakamura K, Matsuzawa N, Ohmori S, et al (2013). Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metab Pharmacokinet, 28, 38-43
27. Nathan C, Xie QW (1994). Nitric oxide synthases. Roles, tolls and controls. Cell, 78, 915-8
28. Neben K, Mytilineos J, Moehler TM, et al (2002). Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263-65
29. Olmos G, Lladó J.(2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm, 2014, 861231
30. Riener EK, Hefler LA, Grimm C, et al (2004). Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. Gynecol Oncol, 93, 686-90
31. Wajant H, Pfizenmaier K, Scheurich P (2003). Tumor necrosis factor signaling. Cell Death Differ, 10, 45-65
32. Wang SS, Davis S, Cerhan JR, et al (2006). Polymorphisims in oxidative stres genes and risk for non-Hodgkin lymphoma. Carcinogenesis, 27, 1828-34